ImaSight Announces Patent Filing and Initiation of Corporate Negotiations

    GATINEAU, QC, Aug. 18 /CNW Telbec/ - ImaSight Corp. (IAS:TSX-V) announced
today that its Liponex division has filed for patent protection of a novel
discovery related to its cardiovascular technology and initiated discussions
with three companies that have expressed an interest in acquiring the Liponex
    Chief Scientist Dr. Daniel Sparks explains that "by uniquely regulating
ATP synthase and nuclear factor kappa B, the Liponex molecules show the
potential to impact cardiovascular disease and raise HDL (good cholesterol)
levels even higher than that shown through the previous Liponex clinical
trials. We have also shown that these novel therapeutics have significant
anti-inflammatory activity and impact specific pathways that may be important
for the prevention and treatment of Alzheimer's disease."
    "While the corporate discussions are in the very early stages", said John
Brooks CEO of ImaSight, "we feel that this new discovery will increase their
interest as we seek to enhance shareholder value." In addition, Liponex
intends to work with the University of Ottawa Heart Institute to seek grant
funding to explore the applications to anti-inflammatory therapeutics.

    About ImaSight

    ImaSight markets its patented digital x-ray sensor at a price affordable
to veterinarians and chiropractors. Its hospital grade sensor has been
approved for sale by Health Canada. Its Liponex division is developing natural
source products for the treatment of cholesterol. Further information can be
found at

    Some of the statements made herein may constitute forward-looking
statements. These statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause ImaSight's actual results, performance or achievements
to be materially different from those expressed or implied by any of the
Company's statements. Actual events or results may differ materially. We
disclaim any intention and assume no obligation to update these
forward-looking statements.

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this release.
    %SEDAR: 00022196EF

For further information:

For further information: John Brooks, CEO, (819) 777-7979 ext. 223,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890